Myriad Genetics (NSDQ:MYGN) subsidiary Myriad Genetics Laboratories said today that the Japanese Ministry of Health, Labor & Welfare approved its Bracanalysis Diagnostic System to be used with Lynparza – a breast cancer drug marketed by AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK).
Lynparza is a PARP inhibitor designed to target deficiencies in DNA damage response pathways. AstraZeneca and Merck are working to get the drug cleared in Japan to treat patients with BRCA-mutated metastatic breast cancer. Myriad’s Bracanalysis test is the first test approved in Japan for use with a PARP inhibitor, the company touted.
Get the full story at our sister site, Drug Delivery Business News.
The post Myriad’s breast cancer diagnostic wins approval in Japan appeared first on MassDevice.